HomeNewsBusinessIIFCL consolidated net profit more than triples in FY21 to Rs 325 crore

IIFCL consolidated net profit more than triples in FY21 to Rs 325 crore

The non-banking financial company said it had brought down its net non-performing assets to 5.4 percent in 2020-21 from around 9.75 percent in 2019-20 and said it aims to reduce NPAs to around 4 percent in 2021-22.

June 22, 2021 / 16:07 IST
Story continues below Advertisement
IIFCL's cumulative sanctions as of March 31 stood at Rs 1.6 lakh crores having risen Rs 20,892 crore in 2020-21 [Image: Shutterstock]
IIFCL's cumulative sanctions as of March 31 stood at Rs 1.6 lakh crores having risen Rs 20,892 crore in 2020-21 [Image: Shutterstock]

India Infrastructure Finance Co Ltd (IIFCL), on June 22, reported a nearly 250 percent jump in its consolidated net profit for 2020-21 (April-March) to Rs 325 crore as the company's sanctions and disbursements soared.

The non-banking financial company said it has brought down its net non-performing assets to 5.4 percent in 2020-21 from around 9.75 percent in 2019-20 and said it aims to reduce NPAs to around 4 percent in 2021-22.

Story continues below Advertisement

The state-owned company's management said on June 22 that it was looking to focus on long-term financing of infrastructure projects in the roads and railways sector to reduce its NPAs.

The company also launched a real-time infrastructure project monitoring system, which it expects will help project financers monitor the development of projects across the country on a real-time basis and will help in reducing delays in the projects. It is also working to set up an in-house research and advisory wing.

COVID-19 Vaccine
Frequently Asked Questions

View more

How does a vaccine work?

A vaccine works by mimicking a natural infection. A vaccine not only induces immune response to protect people from any future COVID-19 infection, but also helps quickly build herd immunity to put an end to the pandemic. Herd immunity occurs when a sufficient percentage of a population becomes immune to a disease, making the spread of disease from person to person unlikely. The good news is that SARS-CoV-2 virus has been fairly stable, which increases the viability of a vaccine.

How many types of vaccines are there?

There are broadly four types of vaccine — one, a vaccine based on the whole virus (this could be either inactivated, or an attenuated [weakened] virus vaccine); two, a non-replicating viral vector vaccine that uses a benign virus as vector that carries the antigen of SARS-CoV; three, nucleic-acid vaccines that have genetic material like DNA and RNA of antigens like spike protein given to a person, helping human cells decode genetic material and produce the vaccine; and four, protein subunit vaccine wherein the recombinant proteins of SARS-COV-2 along with an adjuvant (booster) is given as a vaccine.

What does it take to develop a vaccine of this kind?

Vaccine development is a long, complex process. Unlike drugs that are given to people with a diseased, vaccines are given to healthy people and also vulnerable sections such as children, pregnant women and the elderly. So rigorous tests are compulsory. History says that the fastest time it took to develop a vaccine is five years, but it usually takes double or sometimes triple that time.
View more
+ Show